Currently, the main clinically recommended adjuvant therapies for breast cancer include chemotherapy (anthracycline, taxane, platinum, and capecitabine), targeted therapies (Her2 inhibitor, CD4/6 inhibitor), endocrine therapies (tamoxifen, aromatase inhibitor, ovarian ablation/suppression, and bisphosphonates), and radiotherapy [79,80]. Here, ERBB2 is linked to breast cancer.